IMMUNOVANT, INC. Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage
IMMUNOVANT, INC. (IMVT) had Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage of 100.00% as of 2019-09-30, per its 10-Q filed 2019-11-13.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation
us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage · last filed 2019-11-13
- 2019-09-30: Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage 100.00%.
- 2019-06-30: Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage 100.00%.
- 2019-03-31: Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage 100.00%.
| Period end | Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage |
|---|---|
| 2019-09-30 | 100.00% 10-Q · filed 2019-11-13 |
| 2019-06-30 | 100.00% 10-Q · filed 2019-08-12 |
| 2019-03-31 | 100.00% 10-Q · filed 2019-06-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |